Table 1 Studies on Venetoclax dosing schedule in acute myeloid leukemia (AML): 7 vs 14 vs 21 vs 28 days.
Study | Ven 7 days | Ven 14 days | Ven 21 days | Ven ≥ 21 days | Ven 28 days |
|---|---|---|---|---|---|
Willekens et al. Blood Cancer Journal | ✓ N = 82 | ✓ | ✓ | ✓ N = 111 | ✓ |
CR/CRi | 72% | 72% | |||
Neutropenic fever | 48% | 55% | |||
RBC transfusion | 84% | 83% | |||
Platelet transfusion | 62% | 77% | |||
Overall survival | 11.2 months | 10.3 months | |||
8-week mortality | 6% | 16% | |||
Karrar at al. Am J Hematol | x | ✓ N = 40 | ✓ N = 41 | ✓ N = 189 | |
CR/CRi | 68% | 66% | 62% | ||
≥Grade 3 neutropenia | 45% | 39% | 42% | ||
≥Grade 3 infection | 20% | 18% | 28% | ||
≥Grade 3 thrombocytopenia | 48% | 38% | 41% | ||
Overall survival | 18.6 months | 21.3 months | 13.2 months | ||
Aiba et al. Ann Hematol | x | ✓ N = 8 | x | ✓ N = 13 | |
CR/CRi | 75% | 80% | |||
Neutropenic fever | 38% | 80% | |||
RBC transfusion independence | 88% | 60% | |||
Platelet transfusion independence | 88% | 80% | |||
Overall survival | Not reached | 8.5 months | |||
Kanaya et al. Blood | x | ✓ N = 31 | ✓ N = 51 | ✓ N = 18 | |
CR/CRi | 68% | 51% | 39% | ||
Grade 4 neutropenia | 68% | 78% | 50% | ||
Neutropenic fever | 55% | 47% | 39% | ||
Overall survival | Not reached | 14.3 months | 10.9 months | ||
Ginosyan et al. Blood | x | ✓ N = 11 | ✓ N = 43 | ✓ N = 31 | |
CR/CRi | 27% | 72% | 68% | ||
Overall survival | 6.1 months | 17.6 months | 15.7 months | ||
Cui et al. Hematology | x | ✓ N = 36 | x | x | |
CR/CRi | 68% | ||||
≥Grade 3 neutropenia | 28% | ||||
≥Grade 3 neutropenic fever | 19% | ||||
≥Grade 3 thrombocytopenia | 25% | ||||
Overall survival | 17 months | ||||
